UCEPHAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UCEPHAN (UCEPHAN).
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
| Metabolism | Eculizumab is a monoclonal antibody; it is catabolized via general protein degradation pathways, primarily by the reticuloendothelial system. No specific CYP450 enzyme involvement. |
| Excretion | Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites. |
| Half-life | Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | Approximately 30% bound to serum albumin. |
| Volume of Distribution | 0.2–0.3 L/kg in adults; distributes primarily into extracellular fluid, with limited penetration into cerebrospinal fluid (only when meninges inflamed). |
| Bioavailability | Oral: 20–40% (variable due to first-pass metabolism and food effect). Intramuscular: approximately 90%. |
| Onset of Action | Intravenous: Immediate (within minutes). Intramuscular: 30–60 minutes. Oral: 1–2 hours, delayed by food. |
| Duration of Action | For susceptible infections, bacteriostatic activity persists for 5–8 hours post intravenous dose; clinical effect lasts 12 hours after oral administration. No post-antibiotic effect. |
| Molecular Weight | 444.44 |
500 mg orally every 12 hours or 250 mg orally every 8 hours.
| Dosage form | SOLUTION |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50: 250 mg every 12 hours; GFR 10-29: 250 mg every 24 hours; GFR <10 (not on dialysis): 250 mg every 48 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 12 hours; Child-Pugh C: 250 mg every 24 hours. |
| Pediatric use | 5 mg/kg orally every 12 hours (max 500 mg/dose) for children >1 month. |
| Geriatric use | Use with caution; consider starting at lower dose (250 mg every 12 hours) and titrating based on renal function. |
| 1st trimester | No adequate studies in pregnant women; animal studies show teratogenic effects at high doses. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | Limited human data; may cause fetal harm. Avoid use unless clearly needed. |
| 3rd trimester | May cause adverse effects on fetal bone growth and tooth discoloration if used in late pregnancy. Contraindicated in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for UCEPHAN (UCEPHAN).
| Placental transfer | Crosses placenta; achieves fetal serum levels approximately 50-60% of maternal concentrations. |
| Breastfeeding | UCEPHAN is excreted into breast milk in small amounts. Theoretical risk of dental discoloration and bone growth inhibition in nursing infants. Consider temporary discontinuation of breastfeeding during therapy or use an alternative agent. |
■ FDA Black Box Warning
WARNING: Increased risk of serious or fatal infections due to encapsulated bacteria, including Neisseria meningitidis. Vaccinate patients against meningococcal disease at least 2 weeks prior to administration. Monitor for early signs of infection.
| Serious Effects |
Hypersensitivity to tetracyclinesPregnancy (third trimester)Children under 8 years (permanent tooth discoloration)Severe hepatic impairment
| Precautions | Meningococcal infection risk: Vaccinate and monitor; consider prophylactic antibiotics if urgent treatment needed, Other infections: Increased susceptibility due to complement blockade, Infusion reactions: Discontinue infusion if severe reactions occur, Thrombotic microangiopathy (TMA) complications in aHUS patients following discontinuation |
| Food/Dietary | Avoid alcohol during treatment and for 72 hours after last dose to prevent disulfiram-like reaction. No food restrictions; may be taken with or without food. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | First trimester: No adequate human studies; based on animal data, potential for teratogenicity exists, particularly neural tube defects and cardiac malformations. Second and third trimesters: May cause fetal renal impairment, oligohydramnios, and skull ossification defects with prolonged exposure. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Serial fetal ultrasound for anomalies and growth. Amniotic fluid index assessment due to risk of oligohydramnios. Maternal renal function and blood pressure monitoring. |
| Fertility Effects | No significant adverse effects on fertility reported in animal studies. Human data limited; no expected impact on conception or gametogenesis. |
| Clinical Pearls | UCEPHAN (cefuroxime) is a second-generation cephalosporin with activity against Haemophilus influenzae and Moraxella catarrhalis. Use with caution in penicillin-allergic patients; cross-reactivity occurs in ~10%. For community-acquired pneumonia, it is an alternative to amoxicillin-clavulanate. In surgical prophylaxis, give 1.5 g IV within 60 minutes before incision. Monitor renal function in elderly or those on aminoglycosides. |
| Patient Advice | Take exactly as prescribed; finish the full course even if you feel better. · If you are allergic to penicillin, tell your doctor before taking this medicine. · Common side effects include diarrhea, nausea, and rash; notify your doctor if severe or if you have bloody stools. · Do not take with alcohol; may cause disulfiram-like reaction (headache, flushing, vomiting). · Store at room temperature, away from moisture and heat. |